ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Result of General Meeting
Ananda Developments plc (AQSE: ANA), a life sciences company focused on the research and clinical development of therapies for a range of complex inflammatory pain conditions, is pleased to announce that at the General Meeting of the Company held earlier today, all resolutions were duly passed by shareholders.
Proxy votes received were as follows:
| Resolution No. | Resolution Name | % of Votes For | % of Votes Against | Total Votes Cast (Excluding Withheld) | Number of Votes Withheld |
| 1 Ordinary | To authorise the allotment of securities as set out in the Notice of General Meeting | 99.92% | 0.08% | 1,709,794,105 | 266,399 |
| 2 Special | To waive pre-emption rights over the allotment of securities as set out in the Notice of General Meeting. | 99.92% | 0.08% | 1,709,794,105 | 266,399 |
Accordingly, further to the announcement of 9 September 2024, the Proposed Debt Capitalisation as now been approved and a total of 636,309,333 Ordinary Shares will be issued ("Debt Capitalisation Shares"). Charles Morgan will receive 632,944,000 Ordinary Shares and will therefore hold 2,428,875,896 Ordinary Shares in the Company, representing 56.40 per cent. of the enlarged share capital. Melissa Sturgess will receive 3,365,333 Ordinary Shares and will therefore hold 420,367,118 Ordinary Shares in the Company, representing 9.76 per cent. of the enlarged share capital.
Application to the AQSE Growth Market
Application will be made for the 636,309,333 Debt Capitalisation Shares to be admitted to trading on Access segment of the AQSE Growth Market. It is expected that Admission will become effective on 17 October 2024. The Debt Capitalisation Shares will, on Admission, rank pari passu in all respects with the Ordinary Shares and will rank in full for any dividends and other distributions hereafter declared, paid or made on the ordinary share capital of the Company.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 10.30a.m. on 9 September 2024.
To stay up to date with the latest developments at Ananda, we encourage you to follow and join our social media channels which are:
· Register at our Investor Hub: https://investors.anandadevelopments.com/s/a66906
· Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
· LinkedIn: https://www.linkedin.com/company/anadevelopments/
· Twitter: https://twitter.com/AnandaPlc
· Investor Meet Company: https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
For more information please contact:
| InvestorHub Engage with us directly at Ananda Developments Investor Hub
| Sign up at https://investors.anandadevelopments.com/s/a66906
|
| ANANDA DEVELOPMENTS PLC Chief Executive Officer Melissa Sturgess
Jeremy Sturgess-Smith
| +44 (0)7463 686 497 ir@anandadevelopments.com |
| SP ANGEL CORPORATE FINANCE LLP Corporate Finance Richard Morrison Caroline Rowe | +44 (0)20 3470 0470 |
| Corporate Broking Abigail Wayne Rob Rees
| |
| Yellow Jersey PR Charles Goodwin Zara McKinlay | +44 (0)20 3004 9512
|
About Ananda Developments
Ananda is an AQSE-listed life sciences company focused on the research and clinical development of therapies for a range of complex inflammatory pain conditions.
For further information on the Company visit https://anandadevelopments.com/ or sign up at https://investors.anandadevelopments.com/s/a66906.
https://investors.anandadevelopments.com/link/Wrvx2y
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
